Background. Left ventricular systolic dysfunction (LVSD) is a risk factor for atrial fibrillation (AF),
Introduction
Atrial fibrillation (AF) and congestive heart failure (CHF) frequently co-exist, and left ventricular systolic dysfunction (LVSD) may increase AF risk. 1 The mechanisms of this predisposition to AF likely involve interacting adaptational changes, or remodelling, of atrial structure and electrical, mechanical, metabolic and neurohumoral activities. AF generation and maintenance may each involve atrial reentrant and non-reentrant electrical activity. Reentry is promoted by a shortening of the wavelength, due to a reduction in either the effective refractory period (ERP), conduction velocity, or both. Atrial cellular electrical remodelling in patients with persistent AF features a shortening of the ERP, which is considered to facilitate reentry in these patients. 2 It is conceivable that, in patients who are in sinus rhythm (SR), a predisposition to AF in those with LVSD might involve an associated reduction in the atrial cellular ERP. However, the available data are scarce and conflicting, and often compounded by variability in patients' disease states and drug treatments. 3 In atrial cells isolated from patients with CHF, the action potential duration at 90% repolarisation (APD 90 ), an important determinant of ERP, was either increased, 4 unchanged 5, 6 or, when recorded at relatively high stimulation rate, shortened. 5 A shortening, 6 or no change, 4 in atrial cell APD 50 were also reported.
However, the ERP has not been measured in atrial cells from patients with CHF or LVSD, 3 and also remains to be correlated with the left ventricular ejection fraction (LVEF), an important index of LVSD and predictor of AF. 7 Furthermore, the pattern of ionic remodelling in CHF or LVSD in human atrium also is presently unclear. 3 For example, the L-type Ca 2+ current (I CaL ) was either decreased 8, 9 or unchanged, 5, 10 with either slowed 5 or unchanged 8 kinetics, and had either an increased 9 or decreased 8, 10 response to β-adrenergic stimulation. Studies of human atrial K + currents have shown increased transient outward current (I TO ), with no change in its voltage-dependence or decay, but with enhanced reactivation; 6 a decreased inward rectifier (I K1 ); 4 and an unchanged ultra-rapid delayed rectifier. 6 The aims of this study, therefore, were two-fold. First, to investigate whether LVSD and reduced LVEF in patients who were in SR and undergoing cardiac surgery correlate with a shortening of atrial cellular ERP, which could contribute to a predisposition to AF. Second, to clarify the pattern of any accompanying ionic remodelling, by comparing various ion currents and their voltage-and timedependent characteristics between patients with and without LVSD.
Methods
Right atrial appendage tissue was obtained from 214 consenting patients who were in SR and undergoing cardiac surgery. Procedures were approved by the institutional research ethics committee.
Atrial cells were isolated as described previously. beats/min (bpm) while injecting a small, constant current (set at the start of threshold measurement to clamp the maximum diastolic potential (MDP) to -80 mV, 1-2 min after attaining whole-cell).
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The cellular ERP was then measured using a standard S 1 −S 2 protocol. Ion currents were recorded by voltage-clamping. I K1 was stimulated with linear voltage ramps from -120−+50 mV at 24 mV/s, or with 500 ms pulses (0.2 Hz) increasing from -120−+50 mV in 10 mV steps, from a holding potential (HP) of -50 mV. I TO and the sustained outward current, I SUS , were stimulated with 100 ms pulses (0.33 Hz), from -40−+60 mV, from a -50 mV HP. I SUS was measured as end-pulse current, and I TO as peak outward minus end-pulse current. I CaL was stimulated with 250 ms pulses (0.33 Hz), from -30−+60 mV, from an HP of -40 mV.
Details of each patient's clinical characteristics and drug treatments were obtained from the medical records, post-surgery. All patients were in SR on the day of surgery, confirmed from a presurgery 12 lead ECG. An ECG was also available for the preceding day in 206 of 214 patients, and all confirmed SR. Patients were excluded if they had a documented episode of AF at any time presurgery, if they were taking digoxin or a non-β 1 -selective β-blocker, or if their β 1 -blocker-treatment had started later than 7 days pre-surgery. Each patient was designated as having either "no LVSD", "mild LVSD", "moderate LVSD" or "severe LVSD", from qualitative reports of assessments in the patient's case record. The LVEF was obtained, in a subset of 58 patients, from either echocardiography (52%), radionuclide ventriculography (26%) or contrast ventriculography (22%).
Statistical methods
Univariate measurements were compared between pairs of various subgroups of patients using 2- 
Results

Patients' characteristics
The patients' clinical characteristics and drug treatments are shown in 
Changes in atrial cellular ERP and capacity associated with LVSD
Atrial cells from patients with moderate or severe LVSD had a significantly shorter ERP than those from patients without LVSD ( Figure 1A ). The resting potential (V m ) before current-clamp was similar in patients with moderate or severe LVSD to no LVSD (-20±2 vs -17±1 mV, P>0.05). During currentclamp, the holding current and MDP (taken during ERP-recording) also were similar between these groups (0.72±0.05 vs 0.68±0.03 pA/pF, and -82±1 vs -81±0 mV, respectively; P>0.05 for each). There were no significant differences in other action potential measurements. In a sub-group of 37 patients for whom left atrial (LA) size was available, the LA was larger in patients with LVSD (4.4±0.2 cm, n=7) than in those without (3.8±0.1 cm, n=30; P<0.05). The ERP was similar in cells from patients with LA size≤ 4 cm (clinically recognised as normal 14 ), at 245±22 ms, to those with LA>4 cm, at 256±36 ms (P>0.05), and there was no significant correlation between LA size and ERP (P>0.05).
The right atrial (RA) size was not available, though RA cell capacity was increased in LVSD ( Figure   1C ). The incidence of chronic β 1 -blocker use (which is associated with ERP-prolongation 11, 12 ) in patients from whom ERP was recorded, was 67% in those with moderate or severe LVSD vs 59% in those without LVSD (P>0.05). ERP-shortening associated with LVSD was maintained when patients (Table 2 ).
[Insert Figure 1 ] [Insert Table 2 ]
Correlation between LVEF and atrial cellular electrophysiology
Within the sub-group of 58 patients whose LVEF was available, the qualitative assessment of increasing severity of LVSD was associated with a progressive and significant reduction in LVEF, compared with that recorded in patients without LVSD (Figure 2A ). In patients with LVEF≤ 45% (a clinically accepted threshold for LVSD 14 ), the APD 90 , but not APD 75 or APD 50 , was significantly shorter than in patients with LVEF>45%, by 18% ( Figure 2B ), and the ERP was significantly shorter, by 24% ( Figure 2C ). Furthermore, the action potential maximum upstroke velocity (dV/dtmax) was significantly greater in patients with LVEF≤ 45%, by 11%, than in patients with LVEF>45% ( Figure   2D ). The holding current was similar between these groups (0.67±0.06 vs 0.60±0.04 pA/pF, P>0.05), and there were no significant differences in other action potential measurements. There was a significant correlation (Spearman rank correlation test) between patients' atrial cellular ERP and correlation between dV/dtmax and LVEF with this test (P>0.05). There was also no correlation between LVEF and holding current (P>0.05), nor between ERP and dV/dtmax (P>0.05, n=49 cells).
[Insert Figure 2] Changes in atrial K + currents associated with LVSD Atrial cells from patients with LVSD had a significantly lower peak I TO density (at +60 mV) than patients without LVSD, by 34% ( Figure 3A&B ). This reduction was maintained when patients were sub-analysed by chronic β 1 -blockade (itself associated with I TO -decrease [Insert Figure 3 ] Atrial I CaL characteristics associated with LVSD Peak I CaL density (at +10 mV) was similar in cells from patients with and without LVSD ( Figure   4A&B ). This similarity was maintained in the CABG-only sub-group: -6.0±0. Figure 4C ), and Vact 50 also was similar ( Figure 4D ). I CaL decay was bi-exponential, and both time constants and amplitudes of decay, measured at +10 mV, were similar between patients with and without LVSD ( Figure 4E ). In a sub-group of cells, the magnitude of increase in peak I CaL in response to acute superfusion with either isoproterenol or 5-hydroxytryptamine at near-maximally effective concentrations 13, 15 was assessed.
There was no significant difference between cells from patients with and without LVSD in the response to either drug ( Figure 4F&G ).
[Insert Figure between LVEF<45% and >60%, despite action potential plateau depression. 4, 6 A comparison of the present data with those studies is difficult, however, since they included cells with resting potentials of -50 mV or more positive 4, 6 which would have relatively slow responses, or patients with chronic AF. 4 Furthermore, whilst AF accompanies a number of pathologies, the present cohort was dominated by coronary artery disease. In a single clinical study, CHF was associated with a moderate (≤ 10%) atrial ERP-lengthening at rates ≥ 100 bpm, but lower, physiological, rates were not studied. 16 The relevance of the measurement of the ERP and APD 90 in isolated cells is supported by the demonstration that human chronic AF was associated with shortening of either, or both parameters in atrial isolated cells, 2,15,17 as in atrial isolated tissues, 17, 18 and RA appendages in-vivo. 19 The present ERP-shortening associated with LVSD may be expected, therefore, to contribute to a shortened atrial ERP in-vivo, and consequently, a shortened reentrant wavelength. On the other hand, LVSD was associated with an increase in dV/dtmax, which might oppose wavelength-shortening, by increasing conduction velocity.
However, the dV/dtmax increase was smaller (11%) than the ERP decrease (24%) and, moreover, should increase conduction velocity by only 4%, according to a mathematical model of a cardiac fibre. 20 The combined observed ERP and dV/dtmax changes should, therefore, shorten the wavelength by ~20%.
The consequence of such wavelength-shortening, in the atria of patients in SR with LVSD, would be an increased propensity to reentry. Consistent with that, atrial wavelength-shortening that was produced either by drugs 21 or chronic AF, 22 increased the vulnerability to induction of AF.
Furthermore, CHF or LVSD may cause additional atrial electrophysiological changes that may predispose to AF, particularly in the presence of a shortened wavelength. CHF promoted afterdepolarisations in canine atrial cells, 23, 24 possibly from [Ca 2+ ] i -overload 24 and enhanced Na + /Ca 2+ exchanger current, 25 which might produce triggered activity in-vivo and facilitate the initiation of reentry. Elevated sympathetic tone, which may accompany CHF, could promote such activity.
However, the present experiments with isoproterenol suggest that this would not involve an altered I CaL response to β-stimulation. CHF also causes fibroblasts and collagen to accumulate between fibres or cells of both atria, 26 associated with disturbed local conduction, perhaps facilitating microreentry. 26 Any associated cellular uncoupling may be expected to have a greater influence on conduction velocity than the present change in dV/dtmax, 20 which would result in a correspondingly greater reduction in wavelength and predisposition to AF. Furthermore, atrial fibrosis and susceptibility to AF may persist in CHF after the reversal of ionic remodelling. 27 The ionic changes we found in LVSD and which might, therefore, have contributed to the atrial ERP-shortening, were a reduction in I TO , in line with the shift in its activation voltage. Previous reports of changes in human atrial I TO associated with cardiac disease include a reduction with atrial dilation 28 and an increase with LVSD. 6 However, the latter may have been compounded by the lower proportion of patients treated with β-blockers in the LVSD group, 6 since such treatment is associated with decreased I TO in human atrium. 12 A decreased atrial I TO is also a consistent feature of the canine model of CHF. 25, 29 However, it is unknown what effect a reduction in I TO might have on the human atrial action potential, due to a lack of availability of specific I TO blockers. Mathematical modelling suggested either a shortening or lengthening of APD 90 , depending on which of two human atrial models (which had differing baseline I TO ) was studied. 30 Furthermore, either shortening or lengthening of atrial APD 90 occurred in a canine model, depending on the initial level of I TO . 31 In that model, in support of a link between the present reduction in I TO and APD 90 , a complex coupling of I TO with I CaL was reported such that I TO reduction shortened APD 90 by reducing the driving force and amplitude of I CaL , secondary to phase 1 suppression. 31 The absence of change in I K1 was consistent with studies of 10 of 23 CHF in dogs, 25, 29 although a decrease was reported in 3 patients with CHF. 4 Furthermore, the absence of change in I SUS was consistent with both a human 6 and canine 25 study. The lack of change in I CaL was consistent with two reports of human LVSD, 5,10 although a decrease was also reported, in two others. 8, 9 In the more recent study, 9 I CaL decrease was independently associated with both decreased LV function and mitral valve disease. However, a comparison with the present data is difficult due to differing overall clinical characteristics of the patients between the two studies (e.g., a higher incidence of valvular disease in the Dinanian study 9 ), and is also potentially compounded by the differing recording temperatures and [Ca 2+ ] i -buffering conditions used. The unaltered I CaL voltagedependence and decay were in line with the majority of reports. 5, 8 The action potential dV/dtmax depends predominantly on Na + conductance, determined by Na + current (I Na ) availability, in turn dependent on Na + channel characteristics and diastolic voltage. 20 I Na was not measured here, so the mechanism of dV/dtmax increase associated with LVSD is unknown. However, any contributory changes in I Na availability potentially arising from altered density or time-or voltage-dependence of activation or inactivation would have been independent of diastolic voltage, since this was ~-80 mV in all cells. Increased dV/dtmax could arise from the I TO reduction, since it has been suggested 32 that this current's rapid activation may oppose I Na during phase 0.
The resolution of the ionic mechanisms of the action potential and ERP changes will require measurement of additional currents, as well as [Ca 2+ ] i -handling characteristics, 3 in future studies.
Nevertheless, we demonstrate here that the overall pattern of atrial ionic remodelling associated with LVSD is clearly different from that already associated with human chronic AF, 3 in which both I CaL and I TO were markedly decreased, and I K1 was increased. In line, a disparate pattern of atrial ionic remodelling was also demonstrated in dogs between chronic ventricular tachypacing (VTP)-induced CHF and chronic atrial tachypacing. 29 Furthermore, the present work highlights species-and/or ventricular pathology-dependent differences in atrial ionic remodelling, and the importance of obtaining clinical data. In particular, I CaL was clearly unchanged in the present study, yet moderately decreased in canine VTP-induced CHF. 25, 29 The slow delayed rectifier (I KS ) also was decreased in canine CHF, 25, 29 perhaps contributing to an increase in APD or ERP in some studies of that model 23, 24, 29 (though ERP was unchanged in others 26, 33 ), yet the contribution of I KS to human atrial ERP may be negligible.
Limitations of the study
1:
The enzymatic isolation of myocytes from atrial appendage tissue is recognised to depolarise V m .
We current-clamped V m to overcome this and prevent I Na inactivation. However, whilst un-clamped V m was similar in patients with and without LVSD, V m in-vivo may vary with pathology, with the potential to affect ERP in clamped cells. 2: LV function was assessed qualitatively or quantitatively, rather than uniformly for all patients. 3: The possibility of asymptomatic AF having been missed cannot be excluded.
Clinical implications
The Furthermore, in patients with LVSD post-MI, the non-selective β-blocker carvedilol exerted a powerful atrial anti-arrhythmic effect, even in patients already taking an ACEI.
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Conclusion
The present work contributes to the understanding of the pattern of atrial cellular electrophysiological changes associated with, and potentially caused by, LVSD in patients who underwent cardiac surgery.
The cellular ERP-shortening, which might contribute to a predisposition to AF, may represent a potential therapeutic target for maintaining SR in patients with LVSD. 
